Atea Pharmaceuticals, Inc.

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

Role: lead

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

Role: lead

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

Role: lead

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)

Role: lead

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

Role: lead

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

Role: lead

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin

Role: lead

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

Role: lead

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

Role: lead

Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir

Role: lead

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

Role: lead

Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir

Role: lead

Study of AT-527 in Subjects With Normal and Impaired Renal Function

Role: lead

Study of AT-752 in Patients With Dengue Infection

Role: lead

Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19

Role: collaborator

A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study

Role: collaborator

Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

Role: lead

The Study of Bemnifosbuvir in Healthy Japanese Subjects

Role: lead

Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir

Role: lead

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

Role: lead